AstraZeneca’s Imfinzi on track for EU approval in LS-SCLC treatment

AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), a pharmaceutical giant with a market capitalization of $215.44 billion and impressive gross profit margins of 82.61%, has received a recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its drug Imfinzi (durvalumab) as a treatment for adults with limited-stage small cell lung cancer (LS-SCLC).

According to InvestingPro data, the company maintains strong financial health with a "GREAT" overall score, positioning it well for continued growth in the pharmaceutical sector. The recommendation, announced today, is specifically for patients whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

The CHMP’s favorable opinion is based on the results from the ADRIATIC Phase III trial, which indicated a 27% reduction in the risk of death for patients treated with Imfinzi compared to placebo.

This development comes as AstraZeneca (NASDAQ:AZN) demonstrates robust revenue growth of 13.81% in the last twelve months, reflecting its successful commercialization strategy. InvestingPro analysis reveals 12 additional key insights about AstraZeneca’s financial performance and market position.

The trial’s findings, published in The New England Journal of Medicine, demonstrated an estimated median overall survival (OS) of 55.9 months for Imfinzi-treated patients versus 33.4 months for those receiving placebo. Furthermore, approximately 57% of patients on Imfinzi survived at least three years after treatment, in comparison to 48% for those on placebo.

In addition to improving OS, Imfinzi also showed a 24% reduction in the risk of disease progression or death, extending progression-free survival (PFS) to a median of 16.6 months, compared to 9.2 months for placebo.

Small cell lung cancer is known for its aggressive nature and poor prognosis, with only 15-30% of patients surviving five years post-diagnosis. LS-SCLC, which typically recurs and progresses rapidly despite initial response to CRT, makes up about 15% of all lung cancer cases.

The principal investigator of the ADRIATIC trial, Dr. Suresh Senan, expressed optimism that the CHMP’s recommendation brings European patients closer to accessing a transformative treatment regimen.

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, highlighted the potential of Imfinzi to redefine survival expectations in LS-SCLC, marking the first time patients could have access to immunotherapy in this setting.

Imfinzi’s safety profile was reported as manageable and consistent with its known characteristics, with no new safety concerns arising from the trial.

Already approved in the United States and several other countries for LS-SCLC based on the ADRIATIC trial results, Imfinzi is currently under review in Japan and other markets.

AstraZeneca, a global biopharmaceutical company, is at the forefront of developing innovative medicines for various diseases, with a focus on Oncology, Rare Diseases, and BioPharmaceuticals. This recommendation is a significant step in the company’s commitment to advancing cancer treatment and potentially providing a new therapeutic option for patients with LS-SCLC.

While currently trading at a relatively high P/E ratio of 33.17, InvestingPro’s comprehensive analysis indicates the stock is currently overvalued based on its proprietary Fair Value model. Investors seeking deeper insights can access the detailed Pro Research Report, available for AstraZeneca and 1,400+ other top stocks, offering expert analysis and actionable intelligence for informed investment decisions.

In other recent news, AstraZeneca has been making significant strides in the pharmaceutical landscape. The U.S. Food and Drug Administration (FDA) has approved two of its drugs, Enhertu and Datroway, for the treatment of specific types of breast cancer. These approvals were based on the results of the DESTINY-Breast06 and TROPION-Breast01 Phase III clinical trials respectively, demonstrating significant reductions in the risk of disease progression or death.

AstraZeneca has also announced a $570 million investment in Canada, expected to create over 700 jobs and facilitate a move to a more advanced office facility. This move aligns with the company’s global goal to achieve $80 billion in total revenue and introduce 20 new medicines by 2030.

Analysts from Berenberg and Guggenheim have maintained a Buy rating on AstraZeneca, indicating their confidence in the company’s growth potential. Berenberg set a price target of GBP140, while Guggenheim adjusted its price target to GBP13,100.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.